Drug
Somatrogon clinical trials
Also written MOD-4023.
- studies test it
- 11
- open now
- 1
- in phase 3
- 5
- first study started
- 2009
Keep track of what changes. Save the somatrogon studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 5
Who runs them
Industry 10 · Other 1
OPKO Health, Inc. (9) · Pfizer (1) · Rabin Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses somatrogon is read from its arms, and is right about nine times in ten.
Testing it · 11
- Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.RecruitingPhase 3Rabin Medical CenterNCT07226089Written as Somatrogon
- Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedPhase 3OPKO Health, Inc.NCT02968004Written as MOD-4023
- Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedPhase 2OPKO Health, Inc.NCT02500316Written as MOD-4023
- A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone DeficiencyTerminatedPhase 3OPKO Health, Inc.NCT01909479Written as MOD-4023
- Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHDCompletedPhase 3PfizerNCT03831880Written as somatrogon
- Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone DeficiencyCompletedPhase 3OPKO Health, Inc.NCT03874013Written as MOD-4023
- A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product PresentationsCompletedPhase 1OPKO Health, Inc.NCT03810664Written as Somatrogon
- Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedPhase 2OPKO Health, Inc.NCT01592500Written as MOD-4023
- MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)CompletedPhase 2OPKO Health, Inc.NCT01225666Written as MOD-4023
- Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese VolunteersCompletedPhase 1OPKO Health, Inc.NCT02418767Written as MOD-4023
- MOD-4023 Study in Healthy Male VolunteersCompletedPhase 1OPKO Health, Inc.NCT01060722Written as MOD-4023 (long lasting hGH)
Codes
What other systems call somatrogon · ClinicalTrials.gg INT001166
- MeSH (NLM) C000634267somatrogonOne source NLM
- UNII (FDA) 6D848RA61BSOMATROGONConfirmed FDA, NLM, Wikidata
- Wikidata Q110220159somatrogonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152396SomatrogonOne source FDA
- DrugBank DB14960One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634267 | somatrogon | One source NLM |
| UNII (FDA) | 6D848RA61B | SOMATROGON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q110220159 | somatrogon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152396 | Somatrogon | One source FDA |
| DrugBank | DB14960 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.